SINGAPORE, December 23, 2025 - The "Research Without Borders · Tracing the Source with GeneIII Ergothioneine Global Evidence-Based Journey" officially commenced in Singapore.
GeneIII joined forces with core partners to visit the National University of Singapore (NUS) and the Temasek Life Sciences Laboratory. The event facilitated a deep international dialogue centering on the transformation of Ergothioneine from basic research to industrial application.
This strategic move systematically showcased the complete scientific value chain GeneIII has constructed with NUS and Temasek, achieving a dual track of "Global Layout of Frontier Research" and "Hardcore Brand National Certification," demonstrating the new heights in synthetic biology to the global market.
I. Partnering with Professor Barry Halliwell at NUS to Establish Top-Level Design for Human Clinical Research
The first stop of GeneIII's Global Evidence-Based Journey was a deep dive into its long-term strategic partner—the National University of Singapore. The core of this visit was an in-depth dialogue with the research team of Professor Barry Halliwell, known as the "Authority on Free Radicals" and the "Father of Ergothioneine Research".
Since the formal signing of the research cooperation agreement on February 25, 2025, the project has proceeded efficiently. Professor Halliwell, the founder of the free radical theory of aging, provides fundamental theoretical support for Ergothioneine's core antioxidant and cytoprotective mechanisms through his fifty years of frontier research.[1]
"Substantial evidence indicates that low levels of Ergothioneine (EGT) in the human body are closely related to various age-related degenerative diseases. [2] Exogenous supplementation of EGT shows clear potential in improving neurological function and protecting eye health."[3][4] — Professor Barry Halliwell.
Mr. Ding Wei, Founder and Chairman of GeneIII, described this collaboration as "a historic handshake between scientific theory and industrial practice". Strategic Significance: Professor Halliwell’s profound theoretical results provide top-level scientific guidance and authoritative endorsement for GeneIII's product development.Industrial Empowerment: GeneIII’s synthetic biology technology, achieving 99.99% high-purity, large-scale Ergothioneine mass production[5], provides stable and reliable raw material assurance for Professor Halliwell’s cutting-edge research, solving historical bottlenecks caused by raw material scarcity and high costs.
During the event, Professor Halliwell shared the latest progress in joint research on eye health and brain health, analyzing the mechanism of action of Ergothioneine at the molecular level. This deep binding with NUS allows GeneIII to occupy the high ground of anti-aging theoretical research.
II. Signing with Temasek Life Sciences Laboratory to Initiate the World’s First Human Clinical Study on Ovarian Anti-Aging
For the second stop of the journey, GeneIII visited the Temasek Life Sciences Laboratory to review the global research collaboration on Ergothioneine for ovarian anti-aging, reached in May 2025. This collaboration aims to build a full-chain innovation system of "Basic Research - Mechanism Exploration - Industrial Transformation".
Dr. Yang Qinghua, Director of Intellectual Property and Technology Translation at Temasek Life Sciences Laboratory, highly praised GeneIII’s industrialization capabilities, stating that GeneIII has "reconstructed the global supply chain of Ergothioneine".
Mechanism of Action: "With its excellent mitochondrial protection ability, Ergothioneine is expected to become a key molecular target for delaying reproductive aging," [6][7] Dr. Yang revealed. Current Progress: Both teams are currently utilizing Temasek's advanced platform technologies in gene editing and cell model construction to explore the specific pathways of Ergothioneine in ovarian health.
This partnership marks the extension of GeneIII’s scientific map from basic theory to concrete mechanism and translational research, perfectly complementing the collaboration with NUS.
III. A Heavyweight Co-Branding with State Media Giant People's Daily: Establishing a "Official Recognition + Elite Market" Dual-Trust Ecosystem
A pivotal highlight of this evidence-based journey in Singapore was the global launch of the "GeneIII & People's Daily Co-branded Gift Box." This collaboration holds multifaceted strategic significance. First, as a national high-tech enterprise rooted in Jiangsu, China, GeneIII's complete trajectory—from breakthroughs in synthetic biology to global industrial application—vividly embodies the spirit of industrial innovation. Partnering with People's Daily, the flagship state media outlet, signifies that the GeneIII's research capabilities, product quality, and social value have passed the rigorous scrutiny and received the authoritative endorsement of a national-level platform. "
Secondly, this co-branding is built upon a solid market foundation: GeneIII's Ergothioneine product series has become the shared choice of over one hundred entrepreneurs from Jiangsu's "ten-billion-level" enterprises. The recognition from this elite group, combined with the authoritative certification from People's Daily, jointly constitutes a dual-trust system of "Official Recognition + Market Verification," validating the product's superior efficacy and brand value from multiple dimensions. As the tangible crystallization of the "Hardcore Jiangsu" concept, this co-branded gift box not only carries the credibility of national-level media but also embodies the discerning choices of Jiangsu's business leaders. It allows consumers to directly experience how "hardcore technology" originating from Jiangsu tangibly empowers health and beauty.
This collaboration constructs a multi-dimensional empowerment model featuring "Hardcore Corporate Innovation + National Authoritative Endorsement + Elite Market Verification + Scenario-based Product Realization." This not only endows GeneIII with dual credibility spanning both media and market sectors but also provides a replicable paradigm for other Chinese technology enterprises on how to leverage innovation to win widespread trust and achieve brand elevation. It helps foster an industrial ecosystem that values tangible results and trusts in innovation.
IV. Industry’s First Human Clinical Validation: Building a "Scientific Evidence Moat"
While connecting top theoretical research and mechanism exploration, GeneIII steadfastly adheres to pharmaceutical-grade rigor in human clinical trials as the ultimate verification of product efficacy. GeneIII systematically showcased its Ergothioneine human clinical research matrix, setting a new industry benchmark.
As the first enterprise in the industry to conduct verifiable Ergothioneine human clinical trials in tertiary hospitals, GeneIII ensures scientific rigor and independence.
Key Clinical Research Achievements:
Eye Health: Completed the industry’s first human clinical study on Ergothioneine Eye Wash. Data confirms it significantly improves ocular discomfort and visual fatigue[8].
Liver Protection: Human clinical studies on capsules show that Ergothioneine supplementation significantly improves key liver function indicators in subjects[9].
Frontier Exploration: Studies have been initiated regarding the efficacy and safety of Ergothioneine for postpartum health, sperm vitality, ovarian health, dysmenorrhea, and mild cognitive impairment (MCI)[10].
This series of studies constitutes GeneIII’s strongest "Evidence Moat," directly connecting product efficacy with consumer health benefits through public, traceable human clinical data.
From laying a scientific foundation with top global universities to deepening mechanism transformation with top research institutes; from achieving authoritative brand certification through national-level co-branding to building a solid market trust with rigorous clinical research—GeneIII has completed a three-dimensional display of "Scientific Depth," "Brand Height," and "Evidence Strength" in Singapore.
This comprehensively embodies GeneIII's high-efficiency paradigm for translating Ergothioneine research achievements: establishing a solid foundation of innovation through a robust global R&D layout, elevating brand stature via national authoritative endorsements and elite consensus, and ultimately fortifying market trust with rigorous human clinical evidence—enabling the company to confidently step onto the world stage.
References & Data Sources
[1] Halliwell, B., Cheah, I. K., & Tang, R. M. Y. (2018). Ergothioneine – A diet-derived antioxidant with therapeutic potential. FEBS Letters, 592(20), 3357–3366.
Abstract: A seminal review led by Professor Barry Halliwell. It systematically elucidates Ergothioneine’s unique role as a diet-derived antioxidant and its promising applications in cytoprotection, anti-inflammation, and the potential treatment of diseases such as neurodegeneration and cardiovascular disorders, establishing its foundational theoretical status.
[2] Cheah, I. K., & Halliwell, B. (2021). Ergothioneine, recent developments. Redox Biology, 42, 101868.
Abstract: Published in the prestigious journal Redox Biology, this review summarizes recent progress regarding the human absorption transporter (OCTN1), physiological distribution, and the relationship between EGT levels and aging/disease, alongside its antioxidant and anti-inflammatory mechanisms.
[3] Cheah, I. K., Tang, R., Yew, T., Lim, K., & Halliwell, B. (2017). Administration of pure ergothioneine to healthy human subjects: Uptake, metabolism, and effects on biomarkers of oxidative damage and inflammation. Antioxidants & Redox Signaling, 26(5), 193–206.
Abstract: A pivotal early-stage human clinical trial confirming that oral pure Ergothioneine is effectively absorbed into red blood cells and significantly reduces biomarkers of oxidative damage and inflammation in healthy subjects, providing direct evidence for human application.
[4] Wu, L. Y., Cheah, I. K., et al. (2021). Low plasma ergothioneine levels are associated with neurodegeneration and cerebrovascular disease in dementia. Free Radical Biology and Medicine, 177, 201–211.
Abstract: A critical clinical correlation study finding that lower plasma EGT levels in dementia patients are significantly associated with more severe neurodegeneration and cerebrovascular disease, offering strong epidemiological evidence for EGT's role in maintaining brain health and preventing cognitive decline.
[5] GeneIII Corporate Data: Leveraging synthetic biology, GeneIII has reduced raw material costs by 90%, achieving a monthly capacity of 3-5 tons. Third-party testing (SGS, etc.) confirms an EGT purity of 99.99%. The company holds 33 core patents, including Bacillus chromosome editing technology.
[6] Smith, E., Ott, M., & Peacock, S. (2023). Ergothioneine protects mitochondrial function in mammalian cells under oxidative stress. Free Radical Biology and Medicine, 205, 1–10.
Abstract: This study provides direct cytological evidence of EGT’s mitochondrial protection. It demonstrates that under oxidative stress, EGT effectively maintains mitochondrial membrane potential and ATP production while reducing Reactive Oxygen Species (ROS).
[7] Boots, C. E., & Jungheim, E. S. (2021). The role of mitochondria in ovarian aging. Seminars in Reproductive Medicine, 39(1-02), 33–40.
Abstract: An authoritative review stating that mitochondrial dysfunction (e.g., DNA mutations, ATP deficiency, increased oxidative stress) is the core driver of ovarian aging and declining oocyte quality, providing a theoretical framework for targeting mitochondria to delay reproductive aging.
[8] Clinical Trial Report: Randomized, Open-label, Parallel, Self-controlled Clinical Trial on Ergothioneine Eye Wash for Improving Ocular Discomfort. Registration No.: ChiCTR2400090987.
Key Data: Post-use of GeneIII EGT Eye Wash showed a 24.69% reduction in OSDI scores, a 40.94% reduction in visual fatigue scores, and a 23.60%–27.74% improvement in tear film breakup time.
[9] Clinical Trial Report: Study on the Efficacy and Safety of Ergothioneine Capsules in Improving Liver Function. Registration No.: ChiCTR2400093739.
Key Data: After 30 days of supplementation, subjects' sleep disorder scores decreased by 51.56%, fatigue scores decreased by 39.04%, ALT levels dropped by 21.52%, and AST levels dropped by 19.64%.
[10] Future Research: GeneIII research initiatives regarding mild cognitive impairment (MCI), kidney health, and ovarian health have been successfully registered with the Chinese Clinical Trial Registry (ChiCTR) (e.g., ChiCTR2500112606, ChiCTR2500104484).